 Sridharan Raghavan
Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 30 | 2025 | 2531 | 3.930 |
Why?
| | Cardiovascular Diseases | 11 | 2025 | 2111 | 1.830 |
Why?
| | Diabetes Mellitus | 7 | 2025 | 1040 | 1.640 |
Why?
| | Veterans | 10 | 2025 | 1476 | 1.590 |
Why?
| | Blood Glucose | 15 | 2022 | 2186 | 1.260 |
Why?
| | Hypoglycemic Agents | 6 | 2025 | 1291 | 1.130 |
Why?
| | Life Style | 4 | 2025 | 490 | 1.060 |
Why?
| | Hypertension | 3 | 2025 | 1295 | 0.850 |
Why?
| | Myocardial Infarction | 4 | 2025 | 1046 | 0.840 |
Why?
| | Dementia, Vascular | 1 | 2022 | 20 | 0.790 |
Why?
| | Metformin | 2 | 2025 | 331 | 0.760 |
Why?
| | Genetic Predisposition to Disease | 10 | 2025 | 2426 | 0.750 |
Why?
| | Machine Learning | 4 | 2022 | 493 | 0.750 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2025 | 323 | 0.720 |
Why?
| | Genome-Wide Association Study | 11 | 2025 | 1431 | 0.710 |
Why?
| | Risk Factors | 21 | 2024 | 10388 | 0.700 |
Why?
| | Coronary Artery Disease | 4 | 2022 | 698 | 0.700 |
Why?
| | Hypoglycemia | 1 | 2025 | 445 | 0.690 |
Why?
| | Antihypertensive Agents | 2 | 2025 | 494 | 0.660 |
Why?
| | Alzheimer Disease | 2 | 2023 | 560 | 0.650 |
Why?
| | Early Medical Intervention | 1 | 2019 | 57 | 0.610 |
Why?
| | Genetic Counseling | 1 | 2019 | 77 | 0.600 |
Why?
| | Polymorphism, Single Nucleotide | 11 | 2025 | 2189 | 0.580 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 445 | 0.570 |
Why?
| | Fasting | 4 | 2025 | 281 | 0.560 |
Why?
| | Models, Statistical | 2 | 2021 | 669 | 0.560 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 201 | 0.560 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 388 | 0.550 |
Why?
| | Secondary Prevention | 1 | 2019 | 233 | 0.550 |
Why?
| | Weight Loss | 2 | 2021 | 787 | 0.540 |
Why?
| | Behavior Therapy | 1 | 2019 | 264 | 0.520 |
Why?
| | Population Surveillance | 1 | 2019 | 482 | 0.470 |
Why?
| | Research Design | 2 | 2021 | 1139 | 0.470 |
Why?
| | Humans | 52 | 2025 | 137585 | 0.470 |
Why?
| | Aged | 20 | 2025 | 23961 | 0.450 |
Why?
| | Middle Aged | 24 | 2025 | 33479 | 0.420 |
Why?
| | Risk Assessment | 4 | 2024 | 3457 | 0.420 |
Why?
| | Incidence | 8 | 2025 | 2804 | 0.400 |
Why?
| | Adult | 20 | 2025 | 37929 | 0.390 |
Why?
| | Mycobacterium tuberculosis | 4 | 2008 | 314 | 0.380 |
Why?
| | Social Support | 1 | 2016 | 618 | 0.370 |
Why?
| | Insulin Resistance | 3 | 2021 | 1208 | 0.370 |
Why?
| | Prediabetic State | 2 | 2025 | 253 | 0.360 |
Why?
| | United States | 12 | 2025 | 14841 | 0.350 |
Why?
| | Metabolic Syndrome | 1 | 2015 | 354 | 0.350 |
Why?
| | Retrospective Studies | 11 | 2025 | 15657 | 0.340 |
Why?
| | Virulence Factors | 2 | 2008 | 167 | 0.330 |
Why?
| | Obesity | 4 | 2025 | 2992 | 0.330 |
Why?
| | Male | 28 | 2025 | 67762 | 0.320 |
Why?
| | Female | 28 | 2025 | 73304 | 0.300 |
Why?
| | Follow-Up Studies | 5 | 2025 | 5131 | 0.290 |
Why?
| | Atherosclerosis | 2 | 2024 | 415 | 0.280 |
Why?
| | Bacterial Proteins | 3 | 2008 | 879 | 0.270 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2025 | 26 | 0.240 |
Why?
| | Genetic Variation | 2 | 2025 | 991 | 0.240 |
Why?
| | Survival Rate | 2 | 2019 | 1972 | 0.220 |
Why?
| | Hyperinsulinism | 1 | 2025 | 121 | 0.210 |
Why?
| | Longevity | 1 | 2025 | 165 | 0.210 |
Why?
| | Insulin | 4 | 2025 | 2409 | 0.200 |
Why?
| | Multifactorial Inheritance | 4 | 2025 | 174 | 0.200 |
Why?
| | Biguanides | 1 | 2022 | 12 | 0.190 |
Why?
| | Selection Bias | 1 | 2022 | 37 | 0.190 |
Why?
| | Comorbidity | 2 | 2018 | 1622 | 0.190 |
Why?
| | Calibration | 1 | 2022 | 146 | 0.190 |
Why?
| | Causality | 1 | 2022 | 126 | 0.190 |
Why?
| | Veterans Health | 2 | 2020 | 186 | 0.180 |
Why?
| | Body Height | 1 | 2022 | 199 | 0.180 |
Why?
| | Transcription Factors | 2 | 2016 | 1719 | 0.180 |
Why?
| | Chromosome Mapping | 1 | 2022 | 523 | 0.180 |
Why?
| | Entropy | 1 | 2021 | 41 | 0.180 |
Why?
| | Ambulatory Care | 1 | 2025 | 546 | 0.180 |
Why?
| | Coronary Disease | 1 | 2023 | 385 | 0.180 |
Why?
| | Insurance Carriers | 1 | 2021 | 11 | 0.170 |
Why?
| | Cause of Death | 2 | 2022 | 434 | 0.170 |
Why?
| | Adiposity | 1 | 2025 | 518 | 0.170 |
Why?
| | Probability | 1 | 2021 | 304 | 0.170 |
Why?
| | Colonic Neoplasms | 1 | 2022 | 258 | 0.170 |
Why?
| | Body Mass Index | 4 | 2025 | 2389 | 0.160 |
Why?
| | Diabetic Retinopathy | 1 | 2022 | 189 | 0.160 |
Why?
| | Insulin-Secreting Cells | 1 | 2024 | 377 | 0.160 |
Why?
| | Nutrition Surveys | 1 | 2021 | 266 | 0.160 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2844 | 0.160 |
Why?
| | Macrophages | 5 | 2008 | 1547 | 0.160 |
Why?
| | Precision Medicine | 1 | 2023 | 429 | 0.160 |
Why?
| | Coronary Artery Bypass | 1 | 2021 | 234 | 0.150 |
Why?
| | Guidelines as Topic | 1 | 2021 | 275 | 0.150 |
Why?
| | Insurance, Health | 1 | 2021 | 283 | 0.150 |
Why?
| | Cigarette Smoking | 1 | 2020 | 101 | 0.150 |
Why?
| | Mendelian Randomization Analysis | 3 | 2023 | 50 | 0.150 |
Why?
| | Diabetic Nephropathies | 1 | 2022 | 294 | 0.150 |
Why?
| | Exercise | 2 | 2021 | 2057 | 0.140 |
Why?
| | Case-Control Studies | 1 | 2025 | 3556 | 0.140 |
Why?
| | Patient Readmission | 1 | 2023 | 697 | 0.140 |
Why?
| | Diabetes Complications | 1 | 2019 | 227 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 1050 | 0.130 |
Why?
| | Virulence | 3 | 2008 | 267 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 175 | 0.130 |
Why?
| | Risk | 2 | 2020 | 912 | 0.130 |
Why?
| | Bariatric Surgery | 1 | 2020 | 217 | 0.130 |
Why?
| | Blood Pressure | 2 | 2022 | 1786 | 0.120 |
Why?
| | Obesity, Morbid | 1 | 2020 | 264 | 0.120 |
Why?
| | Refugees | 1 | 2016 | 75 | 0.120 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2021 | 480 | 0.120 |
Why?
| | Mortality | 1 | 2018 | 362 | 0.120 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 315 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1477 | 0.120 |
Why?
| | Family Health | 1 | 2016 | 196 | 0.120 |
Why?
| | United States Department of Veterans Affairs | 3 | 2025 | 678 | 0.120 |
Why?
| | Mutation Rate | 1 | 2015 | 30 | 0.120 |
Why?
| | Spouses | 1 | 2016 | 105 | 0.110 |
Why?
| | Medication Adherence | 1 | 2019 | 467 | 0.110 |
Why?
| | Genotype | 1 | 2020 | 1916 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 910 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 767 | 0.110 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2008 | 328 | 0.110 |
Why?
| | Cardiac Catheterization | 1 | 2018 | 530 | 0.110 |
Why?
| | Emigrants and Immigrants | 1 | 2016 | 136 | 0.110 |
Why?
| | Exome | 1 | 2015 | 231 | 0.110 |
Why?
| | Prognosis | 2 | 2019 | 4030 | 0.100 |
Why?
| | Tuberculosis | 2 | 2008 | 279 | 0.100 |
Why?
| | Heart Failure | 1 | 2025 | 2236 | 0.090 |
Why?
| | Cohort Studies | 4 | 2025 | 5742 | 0.090 |
Why?
| | Age Factors | 1 | 2019 | 3295 | 0.090 |
Why?
| | Stroke | 1 | 2019 | 1120 | 0.090 |
Why?
| | Telemedicine | 1 | 2020 | 862 | 0.090 |
Why?
| | Young Adult | 4 | 2021 | 13209 | 0.080 |
Why?
| | Sample Size | 2 | 2022 | 125 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2828 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2021 | 10811 | 0.080 |
Why?
| | Genomics | 2 | 2025 | 795 | 0.070 |
Why?
| | Mycobacterium marinum | 1 | 2008 | 4 | 0.070 |
Why?
| | Operon | 1 | 2008 | 64 | 0.070 |
Why?
| | Gene Frequency | 2 | 2022 | 521 | 0.070 |
Why?
| | Time Factors | 1 | 2019 | 6828 | 0.070 |
Why?
| | Lysosomes | 1 | 2008 | 141 | 0.070 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2008 | 33 | 0.070 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2020 | 82 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 3715 | 0.070 |
Why?
| | Logistic Models | 2 | 2025 | 2074 | 0.070 |
Why?
| | Toll-Like Receptors | 1 | 2008 | 185 | 0.070 |
Why?
| | Listeria monocytogenes | 1 | 2008 | 126 | 0.060 |
Why?
| | Transcriptional Activation | 1 | 2008 | 378 | 0.060 |
Why?
| | Genetic Loci | 2 | 2020 | 288 | 0.060 |
Why?
| | Phagocytosis | 1 | 2008 | 380 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2008 | 268 | 0.060 |
Why?
| | Glucose | 2 | 2021 | 1020 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2008 | 5757 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2008 | 1457 | 0.060 |
Why?
| | Anthropometry | 1 | 2025 | 213 | 0.060 |
Why?
| | Body Size | 1 | 2025 | 108 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1250 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1946 | 0.050 |
Why?
| | Registries | 2 | 2025 | 2035 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 3196 | 0.050 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2008 | 363 | 0.050 |
Why?
| | Clonal Evolution | 1 | 2023 | 45 | 0.050 |
Why?
| | Hematopoiesis | 1 | 2023 | 192 | 0.050 |
Why?
| | Skilled Nursing Facilities | 1 | 2023 | 141 | 0.050 |
Why?
| | Linkage Disequilibrium | 1 | 2022 | 268 | 0.050 |
Why?
| | Prospective Studies | 2 | 2024 | 7604 | 0.050 |
Why?
| | Europe | 1 | 2022 | 414 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2022 | 102 | 0.040 |
Why?
| | United Kingdom | 1 | 2022 | 318 | 0.040 |
Why?
| | Albuminuria | 1 | 2022 | 185 | 0.040 |
Why?
| | Haplotypes | 1 | 2022 | 494 | 0.040 |
Why?
| | American Heart Association | 1 | 2022 | 306 | 0.040 |
Why?
| | Fee-for-Service Plans | 1 | 2021 | 88 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 683 | 0.040 |
Why?
| | Genome, Human | 1 | 2022 | 425 | 0.040 |
Why?
| | Mice | 5 | 2008 | 17787 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 365 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 217 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 740 | 0.040 |
Why?
| | Decision Trees | 1 | 2018 | 93 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2607 | 0.040 |
Why?
| | Medicare | 1 | 2023 | 773 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2022 | 746 | 0.040 |
Why?
| | Exercise Test | 1 | 2021 | 625 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 554 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 621 | 0.030 |
Why?
| | Patient Discharge | 1 | 2023 | 897 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 1070 | 0.030 |
Why?
| | Massachusetts | 1 | 2016 | 172 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2016 | 99 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 956 | 0.030 |
Why?
| | Glucose-6-Phosphatase | 1 | 2015 | 33 | 0.030 |
Why?
| | Introns | 1 | 2016 | 258 | 0.030 |
Why?
| | Animals | 5 | 2008 | 36940 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2016 | 190 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2008 | 4193 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5472 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2016 | 380 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 2199 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1266 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1710 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2015 | 377 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2017 | 1993 | 0.020 |
Why?
| | Mutation | 1 | 2023 | 3958 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 21513 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3284 | 0.020 |
Why?
| | Mass Screening | 1 | 2019 | 1287 | 0.020 |
Why?
| | Islets of Langerhans | 1 | 2016 | 803 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2016 | 1069 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 7635 | 0.020 |
Why?
| | CARD Signaling Adaptor Proteins | 1 | 2008 | 21 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 6763 | 0.020 |
Why?
| | Caspase 1 | 1 | 2008 | 144 | 0.020 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2008 | 45 | 0.020 |
Why?
| | Cytoskeletal Proteins | 1 | 2008 | 158 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2008 | 188 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2008 | 99 | 0.020 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2008 | 151 | 0.020 |
Why?
| | Macrophage Activation | 1 | 2008 | 201 | 0.020 |
Why?
| | Interleukin-18 | 1 | 2008 | 236 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 195 | 0.020 |
Why?
| | Hemolysis | 1 | 2008 | 206 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4149 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2008 | 372 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 2005 | 67 | 0.020 |
Why?
| | Two-Hybrid System Techniques | 1 | 2005 | 59 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2005 | 110 | 0.010 |
Why?
| | Genes, Bacterial | 1 | 2005 | 164 | 0.010 |
Why?
| | Multigene Family | 1 | 2005 | 198 | 0.010 |
Why?
| | Antigens, Bacterial | 1 | 2005 | 127 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 771 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2003 | 239 | 0.010 |
Why?
| | Plasmids | 1 | 2003 | 363 | 0.010 |
Why?
| | Calcium | 1 | 2008 | 1199 | 0.010 |
Why?
| | Protein Transport | 1 | 2003 | 445 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 2139 | 0.010 |
Why?
| | Child | 1 | 2021 | 21935 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 342 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2900 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2008 | 3015 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2008 | 1774 | 0.010 |
Why?
| | Inflammation | 1 | 2008 | 2837 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1783 | 0.010 |
Why?
| | Signal Transduction | 1 | 2008 | 5079 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2003 | 4295 | 0.010 |
Why?
|
|
Raghavan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|